Orbis Medicines, a Copenhagen, Denmark-based oral macrocycle drug discovery company, raised €90M in Series A funding.
The round was led by NEA with participation from new investors including Eli Lilly and Company, Cormorant, the Export and Investment Fund of Denmark and founding investors Novo Holdings and Forbion.
The company intends to use the funds for the development of pipeline of oral macrocycle drugs, called ‘nCycles,’ focused on validated blockbuster biologic targets.
Led by CEO Morten Graugaard, Orbis Medicines is an oral macrocycle drug discovery company providing a nGen platform that delivers macrocycle candidates, termed nCycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Its pipeline is initially focused on nCycle candidates against targets validated by blockbuster biologic drugs delivered by injection.
In 2024, Orbis raised a EUR 26M series seed round co-led by Novo Holdings and Forbion.
The company is also based in Switzerland.
FinSMEs
06/01/2025